Home  |  Site Map  | Contact
JUL. 30

QLT Announces Second Quarter 2015 Results

   
jun. 8

QLT ANNOUNCES MULTIPLE TRANSACTIONS DESIGNED TO TRANSFORM THE COMPANY AND CREATE SIGNIFICANT NEAR- AND LONG-TERM VALUE FOR SHAREHOLDERS

QLT to Acquire InSite Vision to Create a Diversified, Pure-Play, Late-Stage Ophthalmic Pharmaceutical Company

 

QLT, Deerfield and Other Leading Healthcare Investors to Invest in Aralez Pharmaceuticals, a Newly Formed, Exceptionally Managed, Commercial-Stage, Irish-Domiciled, Specialty Pharmaceutical Company to Be Formed by the Acquisition of Tribute Pharmaceuticals by POZEN, Inc.

 

For more information on these transactions, please visit our Transformative Transactions page.

   
APr. 30

QLT Announces First Quarter 2015 Results

Provides Strategic Review and Synthetic Retinoid Program Update

   
FEB. 26

QLT Announces Fourth Quarter and Year End 2014 Results

Provides Strategic Review and Synthetic Retinoid Program Update

   
JAN. 5

QLT to Appoint Glen Ibbott as Interim Chief Financial Officer

   
   
   
   
   
   
 

To view the “Clinical Proof-of-Concept Study of Oral Synthetic cis-Retinoid (QLT091001) In Adult Subjects with Impaired Dark Adaptation and/or Impaired Low Luminance Vision” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.

 
 
To view the “Vision Improvement After Retreatment with an Oral Synthetic cis-Retinoid (QLT091001) in Subjects with Inherited Retinal Disease caused by Mutations in RPE65 or LRAT” presentation, presented at The ARVO 2015 Annual Meeting, Denver, Colorado, May 3-7, 2015, click here.
   
 
2014 Annual Report
For the Annual Report for the fiscal year ended December 31, 2014, click here.
   
   
   
   
   
   
 
Copyright 2000-2015 QLT Inc. Legal Terms for use of site and Privacy Policy | Disclaimer
Vancouver Web Design by Graphically Speaking
 
Employee Login
 
'ss